Stroke is characterized by an initial ischemia followed by a reperfusion that promotes cascade of damage referred to as primary injury. The loss of mitochondrial function after ischemia, which is characterized by oxidative stress and activation of apoptotic factors is considered to play a crucial role in the proliferation of secondary injury and subsequent brain neuronal cell death. Dopamine D2 receptor agonist, Ropinirole, has been found to promote neuroprotection in Parkinson´s disease and restless leg syndrome. The current study was designed to test its efficacy in preclinical model of stroke. Previously it has been demonstrated that Ropinirole mediates its neuroprotection via mitochondrial pathways. Assuming this, we investigated the effect of Ropinirole on mitochondrial dysfunction, we have shown the positive effect of Ropinirole administration on behavioral deficits and mitochondrial health in an ischemic stroke injury model of transient middle cerebral artery occlusion (tMCAO). Male Wistar rats underwent transient middle cerebral artery occlusion and then received the Ropinirole (10 mg and 20 mg/kg b.w.) at 6 h, 12 and 18 h post occlusion. Behavioral assessment for functional deficits included grip strength, motor coordination and gait analysis. Our findings revealed a significant improvement with Ropinirole treatment in tMCAO animals. Staining of isolated brain slices from Ropinirole-treated rats with 2, 3,5-triphenyltetrazolium chloride (TTC) showed a reduction in the infarct area in comparison to the vehicle group, indicating the presence of an increased number of viable mitochondria. Ropinirole treatment was also able to attenuate mitochondrial reactive oxygen species (ROS) production, as well as block the mitochondrial permeability transition pore (mPTP), in the tMCAO injury model. In addition, it was also able to ameliorate the altered mitochondrial membrane potential and respiration ratio in the ischemic animals, thereby suggesting that Ropinirole has a positive effect on mitochondrial bioenergetics. Ropinirole inhibited the translocation of cytochrome c from mitochondria to cytosol reduces the downstream apoptotic processes. In conclusion, these results demonstrate that Ropinirole treatment is beneficial in preserving the mitochondrial functions that are altered in cerebral ischemic injury and thus can help in defining better therapies.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.neuro.2019.12.004DOI Listing

Publication Analysis

Top Keywords

ropinirole treatment
12
ropinirole
11
mitochondrial
10
mitochondrial dysfunction
8
wistar rats
8
injury model
8
transient middle
8
middle cerebral
8
cerebral artery
8
artery occlusion
8

Similar Publications

The adverse impact of disturbmitochondrialbiogenesis onearly brain injury (EBI) following subarachnoid haemorrhage (SAH) has been broadly recognized and is closely associated with oxidative stress and neuronal apoptosis. Previous studies have indicated the therapeutic potential of Ropinirole, a dopamine D2 agonist, in Ischemic Stroke. However, there is a lack of evidence regarding the ability of Ropinirole to enhance mitochondrial biogenesis and quality control after subarachnoid haemorrhage.

View Article and Find Full Text PDF
Article Synopsis
  • - A patient experienced movement and neurocognitive toxicity after receiving ciltacabtagene autoleucel, which did not improve with standard immunosuppression treatments.
  • - The patient's symptoms responded positively to a combination of dopaminergic therapies, including carbidopa/levodopa, ropinirole, and amantadine.
  • - This case marks the first documented instance of effective symptomatic treatment for a well-known neurotoxic syndrome associated with this therapy.
View Article and Find Full Text PDF

Introduction: This guideline establishes clinical practice recommendations for Treatment of Restless Legs Syndrome (RLS) and Periodic Limb Movement Disorder (PLMD) in adults and pediatric patients.

Methods: The American Academy of Sleep Medicine (AASM) commissioned a task force of experts in sleep medicine to develop recommendations and assign strengths based on a systematic review of the literature and an assessment of the evidence using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) methodology. The task force provided a summary of the relevant literature and the certainty of evidence, the balance of benefits and harms, patient values and preferences, and resource use considerations that support the recommendations.

View Article and Find Full Text PDF

Dopamine agonists in the treatment of Parkinson's disease: the show must go on.

J Neural Transm (Vienna)

December 2024

Parkinson-Klinik Ortenau, Kreuzbergstr. 12-16, 77723, Wolfach, Germany.

Article Synopsis
  • - Dopamine agonists (DA) have been effective in treating Parkinson's disease since the 1990s, particularly in Europe, due to their established efficacy and improved tolerability, along with the availability of longer-lasting preparations.
  • - However, concerns about cardiac issues and impulse control disturbances have led to a reduction in higher doses and a decline in the use of non-ergoline DAs.
  • - Despite these setbacks, DAs remain crucial for treatment alongside levodopa, and their optimized use is essential for the well-being of patients, emphasizing the need for a balanced approach rather than avoiding them altogether.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!